File Ref.: FHB/H/23/4

LEGISLATIVE COUNCIL BRIEF

Pharmacy and Poisons Ordinance (Cap. 138)

PHARMACY AND POISONS (AMENDMENT) REGULATION 2017

INTRODUCTION

The Pharmacy and Poisons Regulations (Cap. 138A) ("the Regulations") was made under section 29 of the Pharmacy and Poisons Ordinance (Cap. 138) ("the Ordinance"). The Pharmacy and Poisons (Amendment) Regulation 2017 ("the Amendment Regulation") at **Annex A** is to amend First, Third and Tenth Schedules to the Regulations.

JUSTIFICATIONS

General Background

2. Under section 29(1B) of the Ordinance, the Pharmacy and Poisons Board ("the Board") set up under section 3 of the Ordinance is empowered to make regulations to amend the Poisons List; or any list of articles or substances in the Regulations, subject to section 31 of the Ordinance and to the approval of the Secretary for Food and Health.

Proposal of the Pharmacy and Poisons Board

3. Arising from applications for registration of four pharmaceutical products, the Board proposes adding the following substances to Division A of First Schedule, Division A of Third Schedule and Division A of Part I of the Poisons List set out in Tenth Schedule to the Regulations:

(a) Alfacalcidol and its salts
(b) Calcitriol and its salts
(c) Vitamin D and its salts when containing in pharmaceutical products the recommended daily dose of which contain more than 1,000I.U. of vitamin D

(d) Vitamin K and its salts when containing in pharmaceutical products, except products with recommended daily dose of 120mcg or less of vitamins K1 or K2 or their salts

4. Besides, the Board also proposes tightening up the sale control of the following class of pharmaceutical products by adding it as a new class entry to Division A of First Schedule, Division A of Third Schedule and Division A of Part I of the Poisons List set out in Tenth Schedule to the Regulations:

(a) Pharmaceutical products for human parenteral administration containing the following list of specified substances and their salts as active ingredients, but except the substances and their salts in mixture with insulin

5. Details of the substances mentioned in paragraphs 3 and 4 above are set out in **Annex B**. In relation to the addition of the new class entry as mentioned in paragraph 4 above, a total of 67 new substances set out in **Annex C** will be put under the above new class entry and subject to the relevant sale control. Moreover, the Board also recommends tightening up the sale control of another 21 substances by re-classifying them under the above new class entry. For details, please refer to **Annex D**. For the sake of consistency, the Board suggests repealing the existing entry of "Paracetamol when contained in pharmaceutical products for human parenteral administration" and adding the substance "Paracetamol" to the list under the above new class entry.

6. The Board considers the proposed amendments appropriate in view of the potency, toxicity and potential side effects of the substances. To allow the trade to have sufficient time to get prepared for the above changes in sale control, the Board recommends that for all the substances except "sodium chloride 0.9%" and "water", the commencement date of the proposed amendments should be six months after the date of gazettal; for only "sodium chloride 0.9%" and "water", the commencement date of the proposed amendments should be twelve months after the date of gazettal.

THE AMENDMENT REGULATION

7. The Amendment Regulation is to add the above drugs (in paragraphs 3, 4 and 5) to the relevant Schedules to the Regulations.

LEGISLATIVE TIMETABLE

8. The legislative timetable will be –

Publication in the Gazette	20 January 2017
Date of Commencement	20 July 2017 or 20 January 2018 (where applicable)

IMPLICATIONS OF THE PROPOSAL

9. The proposal will impose appropriate control on pharmaceutical products consisting of the above substances so that they can be sold in the market upon fulfillment of the relevant regulations.

ENQUIRY

10. For any enquiries, please contact Mr Lam Fong-tat James, Assistant Secretary for Food and Health at 3509 8956.

Food and Health Bureau
January 2017

Pharmacy and Poisons (Amendment) Regulation 2017

(Made by the Pharmacy and Poisons Board under section 29(1B) of the Pharmacy and Poisons Ordinance (Cap. 138) subject to the approval of the Secretary for Food and Health)

1. Commencement

(1) Subject to subsection (2), this Regulation comes into operation on the expiry of 6 months beginning on the day on which it is published in the Gazette.

(2) Sections 3(5), 4(5) and 5(5) come into operation on the expiry of 12 months beginning on the day on which this Regulation is published in the Gazette.

2. Pharmacy and Poisons Regulations amended

The Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) are amended as set out in sections 3, 4 and 5.

3. Schedule 1 amended (substances to which certain restrictions with respect to the sale, supply, labelling and storage apply under regulations 3, 5, 6, 22 and 24)

(1) Schedule 1, Division A, after item "Alendronic acid; its salts"—

Add

"Alfacalcidol; its salts".

(2) Schedule 1, Division A, after item "Calcipotriol; its salts"—

Add

"Calcitriol; its salts".

(3) Schedule 1, Division A—

Repeal item "Paracetamol when contained in pharmaceutical products for human parenteral administration".

(4) Schedule 1, Division A, after item "Pertuzumab"—

Add

"Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin—

Acetic acid

Acetylcholine

Acetylcysteine

Adenosine

Adrenaline

Ambroxol

Amino acids

Aminophylline

Anti-D (rho) immunoglobulins

Anti-histamine substances

Atropine

Betiatide

Bicisate

Butetamate

Caffeine

Carnitine

Cations, the following, except in preparations containing any substance to which the Antibiotics Ordinance (Cap. 137) applies—

Calcium
Chromium
Copper
Iron
Magnesium
Manganese
Potassium
Selenium
Sodium, except sodium chloride 0.9%
Zinc
Choline
Cimetidine
Dextromethorphan
Dicycloverine
Difenidol
Diprophylline
Disofenin
Ephedrine
Exametazime
Fish oil
Fluorescein
Gallium
Gelatin
Glucosamine
Glucose
Glycerol

Glyceryl trinitrate
Guaifenesin
Heparin
Hyaluronic acid
Hyaluronidase
Hydroxyethyl starch
Hyoscine
Icodextrin
Indocyanine green
Iodine norcholesterol
Isosorbide
Lactic acid
Lecithin
Lignocaine
Mannitol
Mebrofenin
Medronic acid
Mesna
Methoxyphenamine
Methylene blue
Methylephedrine
Metronidazole
Noradrenaline
Olive oil
Omeprazole
Oxidronate

Papaverine

Paracetamol

Patent blue V

Pentetic acid

Pentoxifylline

Phenol

Phenylephrine

Piracetam

Procaine

Protamine

Ranitidine

Rhenium

Sodium pyrophosphate

Sodium tetradecyl sulfate

Sodium thiosulfate

Sorbitol

Soya oil

Stonefish antivenom

Succimer

Terbutaline

Tetrakis copper tetrafluoroborate

Tetrofosmin

Thallium

Tin

Triglycerides

Tuberculin

Vitamins

Xantinol nicotinate".

(5) Schedule 1, Division A, item relating to "Pharmaceutical products for human parenteral administration"—

(a) After item "Rhenium"—

Add

"Sodium chloride 0.9%";

(b) After item "Vitamins"—

Add

"Water".

(6) Schedule 1, Division A, after item "Vitamin A and its esters when contained in pharmaceutical products the recommended daily dose of which contains not less than 10,000 international units of vitamin A"—

Add

"Vitamin D and its salts when contained in pharmaceutical products the recommended daily dose of which contains more than 1,000 international units of vitamin D".

(7) Schedule 1, Division A, before item "Voriconazole; its salts"—

Add

"Vitamin K and its salts when contained in pharmaceutical products, except products with recommended daily dose of 120 mcg or less of vitamin K1 or K2 or its salts".

4. Schedule 3 amended (substances required by regulation 9 to be sold by retail only upon a prescription given by a registered medical practitioner, registered dentist or registered veterinary surgeon)

(1) Schedule 3, Division A, after item "Alendronic acid; its salts"—

Add

"Alfacalcidol; its salts".

(2) Schedule 3, Division A, after item "Calcipotriol; its salts"—

Add

"Calcitriol; its salts".

(3) Schedule 3, Division A—

Repeal item "Paracetamol when contained in pharmaceutical products for human parenteral administration".

(4) Schedule 3, Division A, after item "Pertuzumab"—

Add

"Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin—

Acetic acid

Acetylcholine

Acetylcysteine

Adenosine

Adrenaline

Ambroxol

Amino acids

Aminophylline

Anti-D (rho) immunoglobulins

Anti-histamine substances

Atropine

Betiatide

Bicisate

Butetamate

Caffeine

Carnitine

Cations, the following, except in preparations containing any substance to which the Antibiotics Ordinance (Cap. 137) applies—

Calcium

Chromium

Copper

Iron

Magnesium

Manganese

Potassium

Selenium

Sodium, except sodium chloride 0.9%

Zinc

Choline

Cimetidine

Dextromethorphan

Dicycloverine

Difenidol

Diprophylline
Disofenin
Ephedrine
Exametazime
Fish oil
Fluorescein
Gallium
Gelatin
Glucosamine
Glucose
Glycerol
Glyceryl trinitrate
Guaifenesin
Heparin
Hyaluronic acid
Hyaluronidase
Hydroxyethyl starch
Hyoscine
Icodextrin
Indocyanine green
Iodine norcholesterol
Isosorbide
Lactic acid
Lecithin
Lignocaine
Mannitol

Mebrofenin
Medronic acid
Mesna
Methoxyphenamine
Methylene blue
Methylephedrine
Metronidazole
Noradrenaline
Olive oil
Omeprazole
Oxidronate
Papaverine
Paracetamol
Patent blue V
Pentetic acid
Pentoxifylline
Phenol
Phenylephrine
Piracetam
Procaine
Protamine
Ranitidine
Rhenium
Sodium pyrophosphate
Sodium tetradecyl sulfate
Sodium thiosulfate

Sorbitol

Soya oil

Stonefish antivenom

Succimer

Terbutaline

Tetrakis copper tetrafluoroborate

Tetrofosmin

Thallium

Tin

Triglycerides

Tuberculin

Vitamins

Xantinol nicotinate".

(5) Schedule 3, Division A, item relating to "Pharmaceutical products for human parenteral administration"—

(a) After item "Rhenium"—

Add

"Sodium chloride 0.9%";

(b) After item "Vitamins"—

Add

"Water".

(6) Schedule 3, Division A, after item "Vitamin A and its esters when contained in pharmaceutical products the recommended daily dose of which contains not less than 10,000 international units of vitamin A"—

Add

"Vitamin D and its salts when contained in pharmaceutical products the recommended daily dose of which contains more than 1,000 international units of vitamin D".

(7) Schedule 3, Division A, before item "Voriconazole; its salts"—

Add

"Vitamin K and its salts when contained in pharmaceutical products, except products with recommended daily dose of 120 mcg or less of vitamin K1 or K2 or its salts".

5. Schedule 10 amended (Poisons List)

(1) Schedule 10, section 2, Table, Part 1, Division A, after item "Alendronic acid; its salts"—

Add

"Alfacalcidol; its salts".

(2) Schedule 10, section 2, Table, Part 1, Division A, after item "Calcipotriol; its salts"—

Add

"Calcitriol; its salts".

(3) Schedule 10, section 2, Table, Part 1, Division A—

Repeal item "Paracetamol when contained in pharmaceutical products for human parenteral administration".

(4) Schedule 10, section 2, Table, Part 1, Division A, after item "Pertuzumab"—

Add

"Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin—

Acetic acid

Acetylcholine

Acetylcysteine

Adenosine

Adrenaline

Ambroxol

Amino acids

Aminophylline

Anti-D (rho) immunoglobulins

Anti-histamine substances

Atropine

Betiatide

Bicisate

Butetamate

Caffeine

Carnitine

Cations, the following, except in preparations containing any substance to which the Antibiotics Ordinance (Cap. 137) applies—

Calcium

Chromium

Copper

Iron

Magnesium

Manganese

Potassium

Selenium

Sodium, except sodium chloride 0.9%

Zinc

Choline

Cimetidine

Dextromethorphan

Dicycloverine

Difenidol

Diprophylline

Disofenin

Ephedrine

Exametazime

Fish oil

Fluorescein

Gallium

Gelatin

Glucosamine

Glucose

Glycerol

Glyceryl trinitrate

Guaifenesin

Heparin

Hyaluronic acid

Hyaluronidase

Hydroxyethyl starch

Hyoscine

Icodextrin
Indocyanine green
Iodine norcholesterol
Isosorbide
Lactic acid
Lecithin
Lignocaine
Mannitol
Mebrofenin
Medronic acid
Mesna
Methoxyphenamine
Methylene blue
Methylephedrine
Metronidazole
Noradrenaline
Olive oil
Omeprazole
Oxidronate
Papaverine
Paracetamol
Patent blue V
Pentetic acid
Pentoxifylline
Phenol
Phenylephrine

Piracetam
Procaine
Protamine
Ranitidine
Rhenium
Sodium pyrophosphate
Sodium tetradecyl sulfate
Sodium thiosulfate
Sorbitol
Soya oil
Stonefish antivenom
Succimer
Terbutaline
Tetrakis copper tetrafluoroborate
Tetrofosmin
Thallium
Tin
Triglycerides
Tuberculin
Vitamins
Xantinol nicotinate".

(5) Schedule 10, section 2, Table, Part 1, Division A, item relating to "Pharmaceutical products for human parenteral administration"—

(a) After item "Rhenium"—

Add

"Sodium chloride 0.9%";

(b) After item "Vitamins"—

Add

"Water".

(6) Schedule 10, section 2, Table, Part 1, Division A, after item "Vitamin A and its esters when contained in pharmaceutical products the recommended daily dose of which contains not less than 10 000 international units of vitamin A"—

Add

"Vitamin D and its salts when contained in pharmaceutical products the recommended daily dose of which contains more than 1 000 international units of vitamin D".

(7) Schedule 10, section 2, Table, Part 1, Division A, before item "Voriconazole; its salts"—

Add

"Vitamin K and its salts when contained in pharmaceutical products, except products with recommended daily dose of 120 mcg or less of vitamin K1 or K2 or its salts".

Chairman,
Pharmacy and Poisons Board

16 January 2017

Explanatory Note

This Regulation—

(a) adds 4 items to Division A of Schedule 1, and Division A of Schedule 3, to the Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) (***principal Regulations***);

(b) adds 1 item of a class relating to "pharmaceutical products for human parenteral administration" to those Divisions; and

(c) reallocates 1 existing item as an entry under the item mentioned in subparagraph (b) in those Divisions.

The effect is that the sale, supply, labelling and storage of substances in those items are subject to the restrictions imposed under the Pharmacy and Poisons Ordinance (Cap. 138) and the principal Regulations.

2. This Regulation also—

(a) adds 4 items to Division A of Part 1 of the Poisons List set out in Schedule 10 to the principal Regulations;

(b) adds 1 item of a class relating to "pharmaceutical products for human parenteral administration" to that Division; and

(c) reallocates 1 existing item as an entry under the item mentioned in subparagraph (b) in that Division.

The effect is that, among other applicable requirements, substances in those items can only be sold on registered premises of an authorized seller of poisons by a registered pharmacist or in the presence and under the supervision of a registered pharmacist.

Annex B

附件B

Pharmacy and Poisons (Amendment) Regulation 2017

Supplementary Information to the Legislative Council

《2017年藥劑業及毒藥（修訂）規例》

提交立法會的補充資料

Drug Name 藥名	**Proposed Classification** 建議類別	**Reasons** 原因
Alfacalcidol and its salts	Part 1 of the Schedule 10, Schedules 1 and 3 poison	This drug is used for the treatment of neonatal hypocalcaemia, nutritional and malabsorptive rickets, hypophosphataemic vitamin D resistant rickets and osteomalacia. Currently, registered pharmaceutical products containing alfacalcidol are sold without prescriptions. To be on par with the sales control in other countries such as United Kingdom, Australia, Canada and Singapore, these products should be sold upon prescriptions. Side effects include hypercalcaemia and skin reactions. Its use should be decided by a doctor based on the patient's conditions.
阿法骨化醇；其鹽類	附表10的第1部，附表1及附表3毒藥	此藥物用於治療初生嬰兒低鈣血症，營養性及吸收障礙性佝僂病，維生素D耐藥性的低磷血症佝僂病及骨軟化。現時，銷售含阿法骨化醇的註冊藥劑製品時無需醫生處方。為與其他國家例如英國，澳洲，加拿大及新加坡的銷售管制看齊，售賣這些藥物時應需要醫生處方。 副作用包括高鈣血症及皮膚反應。 使用此藥物與否，須由醫生按病人情況決定。

Calcitriol and its salts	Part 1 of the Schedule 10, Schedules 1 and 3 poison	This drug is used for the treatment of abnormalities of calcium and phosphate metabolism in patients with renal osteodystrophy, and for the treatment of post-menopausal osteoporosis. Currently, registered pharmaceutical products containing calcitriol are sold without prescriptions. To be on par with the sales control in other countries such as United Kingdom, Australia, Canada and Singapore, these products should be sold upon prescriptions. Side effects include hypercalcaemia, headache, nausea, vomiting, abdominal pain and constipation. Its use should be decided by a doctor based on the patient's conditions.
骨化三醇；其鹽類	附表10的第1部，附表1及附表3毒藥	此藥物用於治療鈣及磷酸代謝異常，患有腎性骨營養不良的病人，亦用於治療閉經後的骨質疏鬆症。現時，銷售含骨化三醇的註冊藥劑製品時無需醫生處方。為與其他國家例如英國，澳洲，加拿大及新加坡的銷售管制看齊，售賣這些藥物時應需要醫生處方。 副作用包括高鈣血症，頭痛，噁心，嘔吐，腹痛及便秘。 使用此藥物與否，須由醫生按病人情況決定。

Vitamin D and its salts when contained in pharmaceutical products the recommended daily dose of which is more than 1000 international units of vitamin D	Part 1 of the Schedule 10, Schedules 1 and 3 poison	Currently, registered pharmaceutical products containing vitamin D are sold without prescriptions. Vitamin D is fat-soluble and may accumulate in human bodies. To be on par with the sales control in other countries such as United Kingdom, Australia, Canada and Singapore, pharmaceutical products containing vitamin D of the specified concentration should be sold upon prescriptions. Side effects with excessive intake of vitamin D include confusion, constipation, nausea, vomiting, weight loss and kidney impairment. Its use should be decided by a doctor based on the patient's conditions.
維生素D及其鹽類，限於包含在建議每日劑量是超過1000國際單位維生素D的藥劑製品者	附表10的第1部，附表1及附表3毒藥	現時，銷售含維生素D的註冊藥劑製品時無需醫生處方。維生素D屬脂溶性及可能在人體內積聚。為與其他國家例如英國，澳洲，加拿大及新加坡的銷售管制看齊，售賣含指定份量的維生素D的藥劑製品應需要醫生處方。 過度攝取維生素D的副作用包括精神錯亂，便秘，噁心，嘔吐，體重下降及腎功能受損。 使用此藥物與否，須由醫生按病人情況決定。

Vitamin K and its salts when contained in pharmaceutical products, except products with recommended daily dose of 120mcg or less of vitamins K1 or K2 or their salts	Part 1 of the Schedule 10, Schedules 1 and 3 poison	Currently, registered pharmaceutical products containing vitamin K are sold without prescriptions. Vitamin K is fat-soluble and may accumulate in human bodies. To be on par with the sales control in other countries such as United States and Canada, pharmaceutical products containing vitamins K of the specified concentration should be sold upon prescriptions. Adverse effects with excessive intake of vitamin K include abdominal pain, agitation, constipation, hyperbilirubinaemia, increased in liver enzymes, skin eruptions, anaphylaxis and cardiovascular collapse. Its use should be decided by a doctor based on the patient's conditions.
維生素K及其鹽類，限於包含在藥劑製品者，但建議每日劑量為120微克或以下的維生素K1或K2及其鹽類的製品除外	附表10的第1部，附表1及附表3毒藥	現時，銷售含維生素K的註冊藥劑製品時無需醫生處方。維生素K屬脂溶性及可能在人體內積聚。為與其他國家例如美國及加拿大的銷售管制看齊，售賣含指定份量的維生素K的藥劑製品應需要醫生處方。 過度攝取維生素K的副作用包括腹痛，煩躁，便秘，高膽紅素血症，肝酶上升，皮疹，過敏反應及心血管循環衰竭。 使用此藥物與否，須由醫生按病人情況決定。

Pharmaceutical products for human parenteral administration containing the specified substances and their salts as active ingredients, but except the substances and their salts in mixture with insulin	Part 1 of the Schedule 10, Schedules 1 and 3 poison	Currently, some registered pharmaceutical products containing the specified substances for human parenteral use can be sold without prescriptions. To be on par with the sales control in other countries such as the United Kingdom, United States, Australia, Canada and Singapore, these products should be sold upon prescriptions except insulin[1]. It is because insulin should be easily accessible by patients for adequate control of their blood glucose. There are potential safety concerns when patients purchase these products for self-medication or administration without medical consultation and supervision. Its use should be decided by a doctor based on the patient's conditions.
當指定物質及其鹽類載於供人類注射用途的藥劑製品作為有效成分，但胰島素與有關物質及其鹽類的混合物則屬例外	附表10的第1部，附表1及附表3毒藥	現時，有些供人類注射用途的註冊藥劑製品含指定物質，銷售時無需醫生處方。為與其他國家例如英國，美國，澳洲，加拿大及新加坡的銷售管制看齊，除胰島素[2]外，售賣這些藥物時需要醫生處方。因病人需要容易獲得胰島素以便適當地控制其血糖。 如病人在沒有諮詢醫生及其指導下，購買這些藥物供自行使用或給藥，存有潛在的安全後果。 使用此藥物與否，須由醫生按病人情況決定。

[1] Insulin is a Part I poison which must be sold in registered pharmacy by, or under the supervision of, a registered pharmacist.
[2] 胰島素屬第一部毒藥，必須在註冊藥房，由註冊藥劑師或其監督下才可合法售賣。

Annex C

附件C

Specified Substances for Human Parenteral Use for Classification from "Not a Poison" to Schedule 1, Schedule 3 and Part 1 of Schedule 10 Poison under the Pharmacy and Poisons Regulations **由"非毒藥"類別歸類為藥劑業及毒藥規例附表1、附表3及附表10的第1部毒藥類別，供人類注射用途的指定物質**		
No.	**English Name**	**中文名稱**
1.	acetic acid	醋酸
2.	acetylcholine	乙醯膽鹼
3.	acetylcysteine	乙醯半胱氨酸
4.	adenosine	腺苷
5.	ambroxol	氨溴索
6.	amino acids	氨基酸
7.	anti-D (rho) immunoglobulins	抗D免疫球蛋白
8.	betiatide	貝硫肽
9.	bicisate	比西酯
10.	caffeine	咖啡因
11.	carnitine	卡尼汀
12.	the following cations, except when in a preparation containing any substance to which the Antibiotics Ordinance (Cap. 137) for the time being applies: - calcium - chromium - copper - iron - magnesium - manganese - potassium - selenium - sodium, except sodium chloride 0.9%, or - zinc	下列陽離子，但在製劑中含有<抗生素條例>(第137章)當其時適用的物質除外: 鈣 鉻 銅 鐵 鎂 錳 鉀 硒 鈉，但氯化納0.9%除外， 或 鋅
13.	choline	膽鹼
14.	cimetidine	西咪替丁
15.	dicycloverine	雙環維林
16.	difenidol	地芬尼多
17.	diprophylline	二羥丙茶鹼
18.	disofenin	地索苯寧
19.	exametazime	依沙美肟

Specified Substances for Human Parenteral Use for Classification from “Not a Poison” to Schedule 1, Schedule 3 and Part 1 of Schedule 10 Poison under the Pharmacy and Poisons Regulations 由"非毒藥"類別歸類為藥劑業及毒藥規例附表1、附表3及附表10的第1部毒藥類別，供人類注射用途的指定物質		
No.	**English Name**	**中文名稱**
20.	fish oil	魚油
21.	fluorescein	螢光素
22.	gallium	鎵
23.	gelatin	明膠
24.	glucosamine	氨基葡萄糖
25.	glucose	葡萄糖
26.	glycerol	甘油
27.	guaifenesin	愈創甘油醚
28.	heparin	肝素
29.	hyaluronic acid	透明質酸
30.	hyaluronidase	玻璃酸酶
31.	hydroxyethyl starch	羥乙基澱粉
32.	icodextrin	艾考糊精
33.	indocyanine green	吲哚菁綠
34.	iodine norcholesterol	碘化去甲膽固醇
35.	lactic acid	乳酸
36.	lecithin	卵磷脂
37.	mannitol	甘露醇
38.	mebrofenin	甲溴菲寧
39.	medronic acid	亞甲膦酸
40.	mesna	美司鈉
41.	methylene blue	亞甲藍
42.	olive oil	橄欖油
43.	oxidronate	奧昔膦酸
44.	patent blue V	專利藍 V
45.	pentetic acid	噴替酸
46.	pentoxifylline	己酮可哥堿
47.	phenylephrine	去氧腎上腺素
48.	piracetam	吡拉西坦
49.	protamine	魚精蛋白
50.	ranitidine	雷尼替丁

Specified Substances for Human Parenteral Use for Classification from “Not a Poison” to Schedule 1, Schedule 3 and Part 1 of Schedule 10 Poison under the Pharmacy and Poisons Regulations 由"非毒藥"類別歸類為藥劑業及毒藥規例附表1、附表3及附表10的第1部毒藥類別，供人類注射用途的指定物質		
No.	**English Name**	**中文名稱**
51.	rhenium	錸
52.	sodium chloride 0.9%	氯化納0.9%
53.	sodium pyrophosphate	焦磷酸鈉
54.	sodium tetradecyl sulfate	十四烷硫酸鈉
55.	sodium thiosulfate	硫代硫酸鈉
56.	sorbitol	山梨醇
57.	soya oil	大豆油
58.	stonefish antivenom	石魚毒抗血素
59.	succimer	二巯丁二酸
60.	tetrakis copper tetrafluoroborate	〔沒有中文名稱〕
61.	tetrofosmin	替曲膦
62.	tin	錫
63.	triglycerides	甘油三酯
64.	tuberculin	結核菌素
65.	vitamins	維生素
66.	water	水
67.	xantinol nicotinate	尼可占替諾

Annex D

附件D

Specified Substances for Human Parenteral Use for Re-classification to Schedule 1, Schedule 3 and Part 1 of Schedule 10 Poison under the Pharmacy and Poisons Regulations **重新歸類為藥劑業及毒藥規例附表1、附表3及附表10的第1部毒藥類別，** **供人類注射用途的指定物質**		
No.	**English Name**	**中文名稱**
1.	adrenaline	腎上腺素
2.	aminophylline	氨茶鹼
3.	anti-histamine substances	抗組胺物質
4.	atropine	阿托品
5.	butetamate	布替他酯
6.	ephedrine	麻黃鹼
7.	glyceryl trinitrate	硝酸甘油
8.	hyoscine	東莨菪鹼
9.	isosorbide	異山梨醇
10.	lignocaine	利多卡因
11.	methoxyphenamine	甲氧那明
12.	methylephedrine	甲麻黃鹼
13.	metronidazole	甲硝唑
14.	noradrenaline	去甲腎上腺素
15.	omeprazole	奧美拉唑
16.	phenol	苯酚
17.	papaverine	罌粟鹼
18.	procaine	普魯卡因
19.	terbutaline	特布他林
20.	thallium	鉈
21.	dextromethorphan	右甲嗎喃